Accueil   Diary - News   All news EDAP TMS : UCI Health Medical Center Becomes First in the U.S. to Treat Patients Using EDAP's Technology

EDAP TMS : UCI Health Medical Center Becomes First in the U.S. to Treat Patients Using EDAP’s Technology

 

UCI Health, one of the three US medical centers to acquire EDAP's Focal One device, is a recognized leader in prostate cancer diagnosis and treatment utilizing robot-assisted and minimally invasive technologies

 

LYON, France, February 5, 2019 - EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that UCI Health (UCI) has become the first medical center in the United States to treat prostate cancer patients with Focal One, the world's most advanced high intensity focused ultrasound (HIFU) technology. UCI is one of the three medical centers in the country to acquire Focal One, which provides urologists with one of the most precise tools on the market for the targeted, non-invasive ablation of prostate cancer tissue. The outpatient procedure preserves the prostate, enabling the patient to continue to live the best quality of life possible by lowering the incidences of troubling side effects, including impotence and incontinence associated with more invasive legacy treatments such as radical prostatectomy.

 

Read the complete press release

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree